We observed that mRNA expression of A3B and NF-κB components RELA and RELB, as well as an NF-κB gene signature42, were significantly increased in tumors exposed to EGFR TKI treatment, in particular at tumor progression with therapy (Extended Data Fig. 8h–k). This evidence concerns the gene NFKB1 and neoplasm.